Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · IEX Real-Time Price · USD
0.519
+0.005 (0.87%)
Apr 19, 2024, 2:59 PM EDT - Market open
Company Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Evoke Pharma, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Sep 25, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Matthew J. D'Onofrio MBA |
Contact Details
Address: 420 Stevens Avenue, Suite 370 Solana Beach, California 92075 United States | |
| Phone | 858-345-1494 |
| Website | evokepharma.com |
Stock Details
| Ticker Symbol | EVOK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001403708 |
| CUSIP Number | 30049G104 |
| ISIN Number | US30049G2030 |
| Employer ID | 20-8447886 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew J. D'Onofrio MBA | Co-Founder, President, Chief Executive Officer, Chief Operating Officer, Secretary, Treasurer and Director |
| Dr. Marilyn R. Carlson D.M.D., M.D., RAC. | Chief Medical Officer |
| Christopher Quesenberry | Chief Commercial Officer - Gimoti (TM) |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | ARS | Filing |
| Apr 10, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 25, 2024 | 424B3 | Prospectus |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 8-K | Current Report |
| Mar 15, 2024 | POS EX | Filing |
| Mar 15, 2024 | 424B3 | Prospectus |